All posts by: Michael Deninger

Pharmacies dispense medications, and by default are a part of the drug distribution channel. Drug Channels, a blog by Adam Fein, which covers topics across the entire pharmaceutical industry, regularly writes analyses that include pharmacy. The public has a similar perception centered on drug (medication) distribution. The dictionary is also among those that primarily identify pharmacies and pharmacists as distributors......
Continue Reading →
Recently, pharmacies failing to address significant drug interactions has made national headlines. But while the pharmacists that failed to address these interaction are certainly at fault, to some degree we all share in the fault. Today’s healthcare world is regularly pushing providers to do more for less. The payor and the patient both want low cost, and with respect to pharmaceuticals,......
Continue Reading →
Over the last two or three months, we have been observing an accelerating pace of critical news stores focusing the business practices of both the PBM industry and Drug Manufacturers. Now, Rueters is reporting that twenty states are suing Mylan and Teva over drug pricing. Knowing what I do about lawsuits, it will be quite some time before......
Continue Reading →
Among the topics regularly covered on the Thriving Pharmacist are several articles discussing rewards for performance paid to pharmacies. Few of the examples shared here, unfortunately, are actually representative of pay for performance. Today, I will share yet another pay-for-performance program that misses the mark. This program is regional, and is called Intervention Messaging, or IMRx.......
Continue Reading →
This year’s Medicare Part D open enrollment (which ends on Dec. 7th) has turned out to be one of the more interesting  since the program was rolled out more than a decade ago. Previously I reported that our pharmacies elected to drop preferred status with one of the more aggressive plans for 2017. The plan......
Continue Reading →
News articles looking closely at the PBM industry appear to becoming popular. Ken McEldowney, with Morning Consulting takes yet another look at the practices of this middle-man industry. He makes several good observations including: The oligopoly that is the PBM industry not only hurts struggling consumers, it also makes jaw-dropping profits off of them. In......
Continue Reading →
Pharmacy is an interesting business. Unlike most other business models, pharmacy does not completely control the price it charges for services and product. Pharmacy Benefit Managers have leveraged several aspects of contracts and healthcare to remove significant parts of the free market. These include indirect manipulation of a pharmacy’s Usual and Customary Prices, maintaining independent MAC lists, and......
Continue Reading →
Patients and pharmacies are currently in the middle of the 2017 Open Enrollment period for Medicare Part D Prescription Drug Plans. Pharmacies must follow Medicare guidelines if they are helping patients choose a plan in 2017: they cannot guide patients to specific plans that are better for the pharmacy. Pharmacies are limited to providing non-biased facts to......
Continue Reading →
There are more and more opinion pieces addressing the PBM industry. Peter Pitts, writing for Investors.com, has written good summary. Consider this an appetizer for tomorrow’s holiday meal. Enjoy! A Sick Calculation About Prescription Drugs...
Continue Reading →
Darrel Huff’s How to Lie With Statistics is an excellent overview of using mathematics and statistics mislead things that may not actually be true. At the beginning of his book, Huff starts with a quote popularized by Mark Twain and attributed to British Prime Minister Benjamin Disraeli: There are three kinds of lies: lies, damned lies, and statistics. The art of statistical malfeasance is regularly......
Continue Reading →